Company: ABBV
Filing Date: 2025-06-13
Form Type: 11-K
Source: 0001104659-25-059360
Chunk: 24

Company: AbbVie Inc.
Filing Date: 2025-06-13
Form: 11-K
Chunk 24
---
ES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2024 and 2023

NOTE F - TAX STATUS

The Plan has received a determination letter from
the Commonwealth of Puerto Rico’s Department of Treasury (“Treasury”) dated February 6, 2024, stating that the Plan
is qualified under Section 1081.01 of the Puerto Rico Code, and, therefore, the related trust is exempt from taxation. Subsequent to this
determination by the Treasury, the Plan was amended. Once qualified, the Plan is required to operate in conformity with the Puerto Rico
Code to maintain its qualification. The Plan administrator believes the Plan is being operated in compliance with the applicable requirements
of the Puerto Rico Code and, therefore, believes that the Plan, as amended, is qualified and the related trust is tax-exempt.

Accounting principles generally accepted in the
United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization
has taken an uncertain position that more likely than not would not be sustained upon examination by the applicable taxing authorities.
The Plan administrator has analyzed the tax positions taken by the Plan and has concluded that there are no uncertain positions taken
or expected to be taken. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any
tax periods in progress.

NOTE G - SUBSEQUENT EVENTS

The Company has evaluated subsequent events and
there were no subsequent events that require recognition or additional disclosure in these financial statements.

<div align='center'>14

SUPPLEMENTAL SCHEDULE

15</div>

AbbVie Puerto Rico Savings Plan

EIN: 980429860, Plan Number: 002

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

December 31, 2024

(Dollars in thousands)

| Identity of party involved/                                                           
 description of asset                                                                  |     | Cost (a) |     | Current 
 value   |         |
|:--------------------------------------------------------------------------------------|:----|:---------|:----|:--------|--------:|
| *AbbVie Inc., common stock                                                            |     |          |     | $       | 229,322 |
| Abbott Laboratories, common stock                                                     |     |          |     |         |  47,391 |
| Money market fund                                                                     |     |          |     |         |         |
| Vanguard Federal Money Market Fund                                                    |